Fowler A, Collins L, de Ruiter A, Whittaker S, Kulasegaram R, Bradbeer C
Department of Genito-urinary Medicine, Guy's and St Thomas' NHS Foundation Trust, London SE7 7EH, UK.
Int J STD AIDS. 2006 Jan;17(1):63-4. doi: 10.1258/095646206775220522.
Multicentric Castleman's disease (MCD) was originally described in non-HIV patients. It is a rare lymphoproliferative disorder, which is more commonly seen in HIV-positive patients and is associated with human herpes virus-8 (HHV-8). We describe a patient with advanced HIV who responded well to conventional highly active antiretroviral treatment. She was diagnosed with MCD soon after her diagnosis of HIV. She presented with multiple flares of her MCD. The case illustrates the difficulty of differentiating between episodes of septicaemia and a flare of MCD. The patient was treated with various chemotherapy regimens, which included several cycles of liposomal doxyrubicin and etoposide. There is currently no consensus on the treatment of MCD and various therapies are described in the literature, which include chemotherapy. Chemotherapy must be chosen with the immunosuppressive effects of the treatment being considered with caution. Both doxyrubicin and etoposide are well tolerated and successfully controlled the symptoms of MCD in our patient.
多中心Castleman病(MCD)最初是在非HIV患者中被描述的。它是一种罕见的淋巴增殖性疾病,在HIV阳性患者中更常见,且与人类疱疹病毒8型(HHV-8)有关。我们描述了一名晚期HIV患者,其对传统的高效抗逆转录病毒治疗反应良好。她在被诊断出HIV后不久就被诊断出患有MCD。她出现了多次MCD发作。该病例说明了区分败血症发作和MCD发作的困难。该患者接受了多种化疗方案治疗,包括几个周期的脂质体阿霉素和依托泊苷。目前对于MCD的治疗尚无共识,文献中描述了各种疗法,包括化疗。选择化疗时必须谨慎考虑治疗的免疫抑制作用。阿霉素和依托泊苷在我们的患者中耐受性良好,并成功控制了MCD的症状。